Skip to main content
Back to Current Affairs
Science & TechnologySource: The Hindu

NeoSep1 Clinical Trial Enrolls Newborns in India to Combat Antimicrobial-Resistant Neonatal Sepsis

Monday, 13 July 2026
Read Original Article

Key Points

The Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) has enrolled a newborn in the NeoSep1 international clinical trial, focusing on antimicrobial-resistant neonatal sepsis. This is crucial for UPSC aspirants as it relates to GS Paper 2 and 3, covering health and international cooperation. Last Updated: 13-07-2026

Key Facts About NeoSep1 Clinical Trial

  • The NeoSep1 Clinical Trial is a multicentre, international trial sponsored by the Global Antibiotic Research and Development Partnership (GARDP).
  • Aims to enroll 3,000 newborns across Asia and Africa by the end of 2028.
  • Current enrolment locations include Ghana, Kenya, South Africa, India, Vietnam, and Pakistan.
  • Utilizes the PRACTical (Personalised Randomised Controlled Trial) design for real-world applicability.
  • Focuses on identifying effective antibiotic combinations for Low- and Middle-Income Countries (LMICs).
  • India's participation is vital due to its unique pathogen profile causing neonatal sepsis.

India's Strategic Participation in Global Health Trials

India's involvement in the NeoSep1 trial is significant due to its unique pathogen profile, which differs from high-income countries. This participation aligns with India's strategic goals to combat antimicrobial resistance and improve neonatal health outcomes. The trial's findings could enhance India's healthcare strategies and contribute to global health initiatives.

UPSC Relevance

  • GS Paper 2: International relations and health sector initiatives.
  • GS Paper 3: Science and technology, health, and antimicrobial resistance.
  • Prelims: Questions on the NeoSep1 trial, PRACTical design, and GARDP.
  • Mains: Essays on global health cooperation and antimicrobial resistance challenges.

FAQ Section

  • What is the NeoSep1 clinical trial?
    NeoSep1 is an international multicentre clinical trial sponsored by GARDP aimed at identifying safe, effective, and affordable antibiotic combinations for treating neonatal sepsis, particularly in LMICs.
  • What is the PRACTical design used in the NeoSep1 trial?
    The Personalised Randomised Controlled Trial (PRACTical) design allows clinicians to select appropriate antibiotic regimens before randomisation for improved real-world applicability and antimicrobial stewardship.
  • How does India's neonatal sepsis pathogen profile differ from that of high-income countries?
    India’s cases are predominantly caused by multidrug-resistant Gram-negative bacteria, including Klebsiella pneumoniae and Acinetobacter, while Group B Streptococcus is more prominent in high-income countries.
  • Why is India's participation in the NeoSep1 trial significant?
    The trial can generate India-specific evidence on antibiotic regimens, enhance antimicrobial stewardship, improve treatment for drug-resistant neonatal sepsis, and contribute to the reduction of neonatal mortality.

Detailed Coverage

  • NeoSep1 Clinical Trial is an international study by GARDP.
  • Aims to enroll 3,000 newborns by 2028.
  • Current locations: Ghana, Kenya, South Africa, India, Vietnam, Pakistan.
  • Utilizes PRACTical design for personalized treatment.
  • Focuses on effective antibiotic combinations for sepsis.
  • India's inclusion is vital due to unique pathogen profiles.
  • Neonatal sepsis is a severe infection in infants under 90 days.
  • Early-onset sepsis occurs within 72 hours of life.
  • Late-onset sepsis occurs between 72 hours and 90 days.
  • Major pathogens in India include Klebsiella pneumoniae and E. coli.
  • Contributing risk factors: maternal infections, unhygienic practices, and prematurity.
  • Signs include temperature instability, respiratory distress, and neurological symptoms.
  • Immediate treatment with broad-spectrum antibiotics is essential.
  • Neonatal sepsis accounts for 30%-40% of neonatal deaths in India.
  • India's resistance patterns highlight the need for localized evidence.
  • Trial aims to reduce neonatal mortality through effective treatments.
Science & Technology

Practice Questions

Test your understanding of this article

Question 1 of 50 / 5 answered
1

In the context of combating the rising threat of antimicrobial-resistant infections in newborns, which clinical trial aims to enroll a significant number of participants across various countries, including India, to identify effective antibiotic combinations tailored for low- and middle-income countries?